Stockscreener 앱 받기
826.57
1.75%
14.22
시장 영업 전:
825.76
-0.81
-0.10%
전일 마감가:
$812.35
열려 있는:
$812.5
하루 거래량:
2.35M
Relative Volume:
0.52
시가총액:
$782.31B
수익:
$53.26B
순이익/손실:
$13.80B
주가수익비율:
54.81
EPS:
15.0808
순현금흐름:
$-50.20M
1주 성능:
-2.26%
1개월 성능:
+10.48%
6개월 성능:
+9.16%
1년 성능:
-9.50%
1일 변동 폭
$808.58
$830.19
1주일 범위
$806.00
$864.35
52주 변동 폭
$623.78
$935.62
일라이 릴리 Stock (LLY) Company Profile
명칭
Lilly Eli Co
전화
(317) 276-2000
주소
LILLY CORPORATE CTR, INDIANAPOLIS, IN
LLY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
826.57 | 728.24B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
191.17 | 459.63B | 92.15B | 25.12B | 18.18B | 10.36 |
|
ABBV
Abbvie Inc
|
226.22 | 404.77B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
NVS
Novartis Ag Adr
|
129.97 | 252.16B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
MRK
Merck Co Inc
|
84.11 | 211.56B | 63.43B | 16.42B | 14.72B | 6.4861 |
일라이 릴리 Stock (LLY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-17 | 다운그레이드 | Berenberg | Buy → Hold |
| 2025-08-27 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2025-08-18 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | 다운그레이드 | Erste Group | Buy → Hold |
| 2025-04-28 | 다운그레이드 | HSBC Securities | Buy → Reduce |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-09-13 | 재개 | Citigroup | Buy |
| 2024-08-12 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-02-21 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2024-02-16 | 재확인 | Morgan Stanley | Overweight |
| 2023-12-21 | 다운그레이드 | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-10-20 | 재개 | UBS | Buy |
| 2023-08-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-26 | 재확인 | Citigroup | Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-05-24 | 재확인 | BofA Securities | Buy |
| 2023-05-24 | 재확인 | UBS | Buy |
| 2023-03-13 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-02-15 | 다운그레이드 | Societe Generale | Hold → Sell |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-09-22 | 업그레이드 | UBS | Neutral → Buy |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2022-03-10 | 개시 | Daiwa Securities | Outperform |
| 2022-01-21 | 업그레이드 | DZ Bank | Hold → Buy |
| 2022-01-03 | 재확인 | Bernstein | Mkt Perform |
| 2021-12-17 | 개시 | Goldman | Neutral |
| 2021-12-16 | 재확인 | BMO Capital Markets | Outperform |
| 2021-12-16 | 재확인 | BofA Securities | Buy |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-10-11 | 업그레이드 | Berenberg | Hold → Buy |
| 2021-09-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-08-05 | 업그레이드 | DZ Bank | Hold → Buy |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-06-24 | 재확인 | Cantor Fitzgerald | Overweight |
| 2021-01-19 | 업그레이드 | Mizuho | Neutral → Buy |
| 2020-12-10 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-09-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-04-21 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-04-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2019-12-18 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-05-28 | 개시 | Goldman | Buy |
| 2019-04-24 | 업그레이드 | Edward Jones | Hold → Buy |
| 2019-04-11 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-03-12 | 개시 | JP Morgan | Overweight |
| 2019-01-23 | 개시 | UBS | Buy |
| 2018-11-26 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2018-10-31 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | 개시 | Guggenheim | Buy |
| 2018-10-01 | 재확인 | SunTrust | Buy |
| 2018-09-26 | 재개 | JP Morgan | Overweight |
모두보기
일라이 릴리 주식(LLY)의 최신 뉴스
Eli Lilly teams up with Indiana Latino Expo to enhance healthcare access - WISH-TV
Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance
Eli Lilly taps Goldman Sachs Asset Management for $25 billion OCIO deal - Pensions & Investments
Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead - MarketBeat
Lilly's oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes - investor.lilly.com
Eli Lilly's Oral Weight Loss Drug Shows Superiority Over Two Approved Drugs - Benzinga
Eli Lilly Stock Price ForecastLLY Soars to $860 After Orforglipron Breakthrough - TradingNEWS
Eli Lilly: Outstanding Orforglipron Data Reinforces Value Proposition (NYSE:LLY) - Seeking Alpha
Lilly’s Oral GLP-1 Bests Another Big Pharma Bestseller in Phase III Diabetes Trial - BioSpace
Lilly's weight-loss pill shows better blood sugar control in late-stage trials - Reuters
Eli Lilly's orforglipron bests Farxiga, padding oral GLP-1 case with pair of phase 3 diabetes wins - Fierce Biotech
Eli Lilly (LLY) Advances Diabetes Treatment with Orforglipron Su - GuruFocus
Eli Lilly (LLY) Reports Promising Phase 3 Trial Results for Diab - GuruFocus
Eli Lilly oral obesity drug succeeds in diabetes trial (LLY) - Seeking Alpha
Lilly, battling skepticism, reinforces GLP-1 pill’s case with new study data - Yahoo Finance
Driven by the Engine of Innovation, Eli Lilly Leads a New Era in Healthcare - NAI500
FDA Approves Alzheimer’s Test Developed By Roche In Collaboration With Eli Lilly - Stocktwits
Major Shareholder Sells Millions in Eli Lilly Stock! - TipRanks
1 Reason Eli Lilly (LLY) Is One of the Best Healthcare Stocks You Can Buy Today - The Globe and Mail
Lilly Endowment sells $3.16 million in Eli Lilly shares - Investing.com
Eli Lilly eyes 2027 approval for new obesity drug: CEO - Nikkei Asia
Independence Bank of Kentucky Buys Another $3.1 Million Eli Lilly (NYSE: LLY) Shares - The Globe and Mail
Eli Lilly (LLY) Upgraded to 'Buy' Amid Promising Growth Catalysts - GuruFocus
Eli Lilly doubles down on Mounjaro despite rising competition in Brazil - Valor International
The Zacks Analyst Blog Highlights Apple, Eli Lilly and Visa - Nasdaq
Erste Group upgrades Eli Lilly stock rating to Buy after strong H1 results - Investing.com Canada
Top Stock Reports for Apple, Eli Lilly & Visa - Nasdaq
Eli Lilly and Company Strengthens Presence Among S&P 500 Companies - Kalkine Media
Eli Lilly: The Rally Has More Room To Run (Rating Upgrade) (NYSE:LLY) - Seeking Alpha
Lilly Wants To Know: What Does Chronic Illness Really Look Like? 10/13/2025 - MediaPost
Precision Trading with Eli Lilly And Company (LLY) Risk Zones - news.stocktradersdaily.com
Eli Lilly Omvoh Demonstrates Sustained Long-Term Benefits in Ulcerative Colitis Up to Four Years - Yahoo Finance
Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (Oct 2025) - 24/7 Wall St.
Eli Lilly Opens R&D Incubator for Life Sciences Startups - San Diego Business Journal
Aspen wins approval to market Lilly's Mounjaro for weight loss in South Africa - Reuters
Should Omvoh’s Clinical Success and Earnings Optimism Prompt Action from Eli Lilly (LLY) Investors? - simplywall.st
Should Omvoh’s Clinical Results and Innovation Drive a Rethink of Eli Lilly’s (LLY) Specialty Focus? - Yahoo Finance
The Goldman Sachs Group Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price - MarketBeat
Insider Sales Surge: Block, Eli Lilly, Strategy, P&G, Dell - TipRanks
Eli Lilly and Company (NYSE:LLY) Stock Unloaded Rep. Val T. Hoyle - MarketBeat
Should Investors Buy Eli Lilly Stock? - The Globe and Mail
Meet this year’s Women in Biopharma; Peter Marks goes to Eli Lilly; Bob Langer startup launches; and more - Endpoints News
Gunderson Capital Management Inc. Increases Position in Eli Lilly and Company $LLY - MarketBeat
Seeking Safe Havens: Why Pfizer and Eli Lilly Are Top Market Picks Now? - NAI500
Eli Lilly (LLY): Revisiting Valuation After Recent Share Price Gains - simplywall.st
Lilly Endowment sells Eli Lilly shares worth $9.04 million - Investing.com
Eli Lilly and Co(LLY.US) 10% Shareholder Sells US$9.04 Million in Common Stock - 富途牛牛
Lilly Endowment unloads about $600 million in Eli Lilly stock during early October - Sherwood News
Eli Lilly’s New Study on Weight Reduction Drugs: A Potential Market Game-Changer? - TipRanks
Next medicine deal after Pfizer? Analysts, shares point to AstraZeneca, Eli Lilly - Reuters
Next Medicine Deal After Pfizer? Analysts, Shares Point to AstraZeneca, Eli Lilly - Money US News.com
일라이 릴리 (LLY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.17%
1.27%
자본화:
|
볼륨(24시간):